About Novavax, Inc.
https://www.novavax.comNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
CEO
John Charles Jacobs
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-05-10 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
B. Riley Securities
Buy
HC Wainwright & Co.
Buy
TD Cowen
Hold
JP Morgan
Underweight
B of A Securities
Underperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:15.19M
Value:$124.44M
BLACKROCK, INC.
Shares:12.77M
Value:$104.61M
BLACKROCK INC.
Shares:11.85M
Value:$97.02M
Summary
Showing Top 3 of 300
About Novavax, Inc.
https://www.novavax.comNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $70.44M ▼ | $226.97M ▲ | $-202.38M ▼ | -287.29% ▼ | $-1.25 ▼ | $-190.97M ▼ |
| Q2-2025 | $239.24M ▼ | $119.34M ▼ | $106.51M ▼ | 44.52% ▼ | $0.66 ▼ | $120.53M ▼ |
| Q1-2025 | $666.65M ▲ | $137.03M ▼ | $518.65M ▲ | 77.8% ▲ | $3.22 ▲ | $533.91M ▲ |
| Q4-2024 | $88.31M ▲ | $182.72M ▲ | $-81.03M ▲ | -91.76% ▲ | $-0.51 ▲ | $-53.48M ▲ |
| Q3-2024 | $84.51M | $157.91M | $-121.3M | -143.53% | $-0.76 | $-105.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $762.89M ▲ | $1.18B ▼ | $1.34B ▲ | $-156.67M ▼ |
| Q2-2025 | $612.3M ▼ | $1.34B ▲ | $1.3B ▼ | $37.63M ▲ |
| Q1-2025 | $731.48M ▼ | $1.29B ▼ | $1.37B ▼ | $-75.64M ▲ |
| Q4-2024 | $923.12M ▲ | $1.56B ▼ | $2.18B ▼ | $-623.84M ▼ |
| Q3-2024 | $909.53M | $1.71B | $2.24B | $-526.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-202.38M ▼ | $107.8M ▲ | $-136.53M ▼ | $42.44M ▲ | $14.35M ▲ | $105.79M ▲ |
| Q2-2025 | $106.51M ▼ | $-127.46M ▲ | $111.1M ▲ | $-1.04M ▲ | $-9.5M ▲ | $-127.71M ▲ |
| Q1-2025 | $518.65M ▲ | $-185.5M ▼ | $-73.32M ▼ | $-7.06M ▼ | $-266.81M ▼ | $-187.1M ▼ |
| Q4-2024 | $-81.03M ▲ | $-173.16M ▼ | $144.01M ▲ | $-3.42M ▼ | $-43.3M ▲ | $-175.41M ▼ |
| Q3-2024 | $-121.3M | $-144.81M | $31.91M | $-97K | $-106.97M | $-146.83M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Nuvaxovid Sales | $0 ▲ | $0 ▲ | $0 ▲ | $610.00M ▲ |
 Product | $50.00M ▲ | $10.00M ▼ | $10.00M ▲ | $0 ▼ |
 Royalties and Other | $40.00M ▲ | $0 ▼ | $0 ▲ | $40.00M ▲ |
 Supply Sales | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 CANADA | $0 ▲ | $0 ▲ | $0 ▲ | $580.00M ▲ |
 Europe | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Rest Of The World | $40.00M ▲ | $40.00M ▲ | $10.00M ▼ | $40.00M ▲ |
 UNITED STATES | $0 ▲ | $200.00M ▲ | $60.00M ▼ | $40.00M ▼ |
CEO
John Charles Jacobs
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-05-10 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
B. Riley Securities
Buy
HC Wainwright & Co.
Buy
TD Cowen
Hold
JP Morgan
Underweight
B of A Securities
Underperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:15.19M
Value:$124.44M
BLACKROCK, INC.
Shares:12.77M
Value:$104.61M
BLACKROCK INC.
Shares:11.85M
Value:$97.02M
Summary
Showing Top 3 of 300